Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone

Paolo Massaro, Paolo Foa, Mauro Pomati, Maria Luisa LaTargia, Alessandra Iurlo, Claudia Clerici, Sarah Caldiera, Monica Fornier, Anna Teresa Maiolo

Research output: Contribution to journalArticlepeer-review

Abstract

We periodically analyzed bone-marrow cytogenetic features in 8 patients belonging to a series of 38 subjects with polycythemia vera (PV), all treated with recombinant interferon-alpha 2a (rIFN-alpha) at a weekly dose of 9,000,000 IU. Six out of these 8 patients never showed any chromosome alterations, while 2 displayed at diagnosis the presence of trisomy 8 in all bone-marrow metaphases. Interestingly enough, in these 2 patients rIFN-alpha treatment was able to induce not only complete hematological response but also the disappearance of trisomy 8, as shown by conventional cytogenetic investigation and fluorescence in situ hybridization performed on bone- marrow cells after I year of treatment. This finding indicates that, as previously shown in chronic myeloid leukemia, in PV rIFN-alpha can also eradicate the malignant clone by means of a selective effect on bone-marrow transformed cells.

Original languageEnglish
Pages (from-to)126-128
Number of pages3
JournalAmerican Journal of Hematology
Volume56
Issue number2
DOIs
Publication statusPublished - Oct 1997

Keywords

  • Cytogenetics
  • Fluorescence in situ hybridization
  • Interferon-alpha
  • Polycythemia vera

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone'. Together they form a unique fingerprint.

Cite this